{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:37:05Z","timestamp":1791581825435,"version":"4.3.4"},"reference-count":41,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2022,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>This phase 2b, randomized, observer-masked, placebo- and active-controlled, parallel-group, multinational (USA and Japan), multicenter study (NCT03216902) assessed the optimal dose of sepetaprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      After washout, patients \u226518 years (USA) or \u226520 years of age (Japan) received once-daily sepetaprost for 3 months [0.0005% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200943); 0.001% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200943); 0.002% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200944); and 0.003% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200945)], latanoprost 0.005% (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200944) or placebo until week 6, followed by sepetaprost 0.003% until month 3 (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200922). Safety assessments included adverse event (AE) occurrence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Baseline mean diurnal intraocular pressure (IOP) was 24.3\u2009mmHg for latanoprost and ranged between 24.1 and 24.5\u2009mmHg for the sepetaprost groups. Sepetaprost 0.002% had the lowest IOP at each month 3 time point (9:00 AM; 1:00 PM; 5:00 PM) of all sepetaprost concentrations (mean\u2009\u00b1\u2009standard error: 17.6\u2009\u00b1\u20090.5; 17.4\u2009\u00b1\u20090.4; 16.7\u2009\u00b1\u20090.4\u2009mmHg); similar values were observed with latanoprost (18.1\u2009\u00b1\u20090.6; 17.3\u2009\u00b1\u20090.5; 17.2\u2009\u00b1\u20090.5\u2009mmHg). A positive dose\u2013response relationship was observed with the 3 lower sepetaprost doses; sepetaprost 0.002% had numerically greater IOP-lowering effects than sepetaprost 0.003%. All sepetaprost doses had statistically significantly greater IOP reductions from baseline versus placebo at week 6 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.0001). This IOP-lowering effect was consistent between Japan- and USA-based patients. Most AEs were mild and occurred numerically less frequently with sepetaprost 0.002% (34.1%) versus latanoprost (50.0%). The most frequently reported AE was conjunctival hyperemia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In this study, sepetaprost 0.002% was the optimal concentration, showing comparable IOP-lowering efficacy and safety with latanoprost 0.005%. Most AEs were mild; occurrence was numerically lower with sepetaprost 0.002% than latanoprost 0.005%.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2021.0077","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T17:14:00Z","timestamp":1644945240000},"page":"240-251","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Phase 2b, Randomized, 3-Month, Dose-Finding Study of Sepetaprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: The ANGEL Study"],"prefix":"10.1177","volume":"38","author":[{"given":"David L.","family":"Wirta","sequence":"first","affiliation":[{"name":"Eye Research Foundation, Newport Beach, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Kuwayama","sequence":"additional","affiliation":[{"name":"Fukushima Eye Clinic, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghe","family":"Lu","sequence":"additional","affiliation":[{"name":"Product Development Division (FHL, HS), Santen, Inc., Emeryville, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Shao","sequence":"additional","affiliation":[{"name":"Product Development Division (FHL, HS), Santen, Inc., Emeryville, California, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Odani-Kawabata","sequence":"additional","affiliation":[{"name":"Product Development Division (FHL, HS), Santen, Inc., Emeryville, California, USA."},{"name":"Product Development Division (NOK), Santen Pharmaceutical Co., Ltd., Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,4,6]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3192"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.05.013"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjo.2016.07.013"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.10.1268"},{"key":"e_1_3_5_6_2","first-page":"429","article-title":"The Advanced Glaucoma Intervention Study (AGIS): 7","volume":"130","author":"AGIS (Advanced Glaucoma Intervention Study) Investigators","year":"2000","unstructured":"AGIS (Advanced Glaucoma Intervention Study) Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol. 130:429\u2013440, 2000.","journal-title":"The relationship between control of intraocular pressure and visual field deterioration"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00055735-200304000-00010"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2014.04.003"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62111-5"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.10.022"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.3274"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0000000000001342"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.02.016"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.10.053"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1016-1"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0877-7"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0333-2"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2014.0067"},{"key":"e_1_3_5_19_2","first-page":"1967","article-title":"Latanoprost in the treatment of glaucoma","volume":"8","author":"Alm A.","year":"2014","unstructured":"Alm A. Latanoprost in the treatment of glaucoma. Clin. Ophthalmol. 8:1967\u20131985, 2014.","journal-title":"Clin. Ophthalmol"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/17469899.2021.1935241"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S63760"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.120.6.701"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2004.12.026"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01277-2"},{"key":"e_1_3_5_25_2","first-page":"1436","article-title":"G, and VISIONARY Study Group","volume":"37","author":"Oddone F.","year":"2020","unstructured":"Oddone F., , Tanga L., , K\u00f3thy P., Holl\u00f3 G, and VISIONARY Study Group. Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost\/timolol fixed-dose combination therapy: the VISIONARY study. Adv. Ther. 37:1436\u20131451, 2020.","journal-title":"Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost\/timolol fixed-dose combination therapy: the VISIONARY study"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2016-EGSguideline.003"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0000000000000449"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-16181"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.15-18166"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-307000"},{"key":"e_1_3_5_31_2","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice 2016. Available at: https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf. Accessed January31 2022."},{"key":"e_1_3_5_32_2","first-page":"2191","article-title":"Declaration of Helsinki","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human subjects. JAMA. 310:2191\u20132194, 2013.","journal-title":"Ethical Principles for Medical Research Involving Human subjects"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2415-12-9"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2009.12.003"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.01.042"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2012-303026"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1319628"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2016-309023"},{"key":"e_1_3_5_39_2","first-page":"741","article-title":"Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension","volume":"4","author":"Lee A.J.","year":"2010","unstructured":"Lee A.J., , and McCluskey P. Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension. Clin. Ophthalmol. 4:741\u2013764, 2010.","journal-title":"Clin. Ophthalmol"},{"key":"e_1_3_5_40_2","unstructured":"U.S. Food & Drug Administration (FDA). XALATAN\u00ae: prescribing information (PI). Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/020597s052lbl.pdf Accessed June16 2021."},{"key":"e_1_3_5_41_2","unstructured":"ClinicalTrials.gov. NCT04742283. Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension (ANGEL-2). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04742283. Accessed January27 2022."},{"key":"e_1_3_5_42_2","unstructured":"EU Clinical Trials Register. EU Clinical Trials Register_2020-004836-93: An Exploratory Study to Assess the 24-hour Intraocular Pressure (IOP) Lowering Characteristics Duration of Action and Safety of DE-126 ophthalmic solution 0.002% versus Latanoprost ophthalmic solution 0.005% in Subjects with Primary Open Angle Glaucoma or Ocular Hypertension. Available at: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-004836-93\/GR. Accessed January27 2022."}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2021.0077","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2021.0077","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2021.0077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:44:44Z","timestamp":1777646684000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2021.0077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4,1]]}},"alternative-id":["10.1089\/jop.2021.0077"],"URL":"https:\/\/doi.org\/10.1089\/jop.2021.0077","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]}}}